Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mizolastine

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,197Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 108612-45-9, Mizollen, Zolistan, Sl 85.0324, Mistamine, 2-((1-(1-(p-fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3h)-pyrimidinone
    Molecular Formula
    C24H25FN6O
    Molecular Weight
    432.5  g/mol
    InChI Key
    PVLJETXTTWAYEW-UHFFFAOYSA-N
    FDA UNII
    244O1F90NA
    Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
    2.1.2 InChI
    InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
    2.1.3 InChI Key
    PVLJETXTTWAYEW-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5
    2.2 Other Identifiers
    2.2.1 UNII
    244O1F90NA
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Mistalin

    2. Mistamine

    3. Mizolen

    4. Mizollen

    5. Sl 85.0324

    6. Sl-85.0324

    7. Zolim

    8. Zolistan

    2.3.2 Depositor-Supplied Synonyms

    1. 108612-45-9

    2. Mizollen

    3. Zolistan

    4. Sl 85.0324

    5. Mistamine

    6. 2-((1-(1-(p-fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3h)-pyrimidinone

    7. Mizolastine (mizollen)

    8. Mkc-431

    9. Chembl94454

    10. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1h-pyrimidin-6-one

    11. Mistalin

    12. 244o1f90na

    13. Mizolastine [inn]

    14. Ncgc00181013-01

    15. Mizolastina

    16. Mizolastinum

    17. Mizolen

    18. Zolim

    19. Dsstox_cid_26801

    20. Dsstox_rid_81916

    21. Dsstox_gsid_46801

    22. 2-((1-(1-(4-fluorobenzyl)-1h-benzo[d]imidazol-2-yl)piperidin-4-yl)(methyl)amino)pyrimidin-4(3h)-one

    23. 2-[[1-[1-[(4-fluorophenyl)methyl]benzoimidazol-2-yl]-4-piperidyl]-methyl-amino]-3h-pyrimidin-4-one

    24. Mizolastinum [inn-latin]

    25. Mizolastina [inn-spanish]

    26. Zolistam

    27. 2-{1-[1-(4-fluorobenzyl)-1h-benzimidazol-2-yl]-4-piperidyl(methyl)amino}pyrimidin-4(1h)-one

    28. Sl-85.0324

    29. Mizollen (tn)

    30. 2-((1-(1-(4-fluorobenzyl)-1h-benzo[d]imidazol-2-yl)-piperidin-4-yl)(methyl)amino)pyrimidin-4(1h)-one

    31. Cas-108612-45-9

    32. Mizolastine (jan/inn)

    33. Mizolastine [inn:ban]

    34. Unii-244o1f90na

    35. Ccris 8410

    36. Sl 850324

    37. Mizolastine [mi]

    38. Mizolastine [jan]

    39. Schembl5061

    40. Mizolastine [mart.]

    41. Mizolastine [who-dd]

    42. Mls006010068

    43. Mkc431

    44. Dtxsid5046801

    45. Bdbm22877

    46. Chebi:31857

    47. Gtpl10102

    48. Hms3713n04

    49. Hy-b0164

    50. Tox21_112663

    51. Ac-634

    52. Mfcd23140913

    53. Zinc13831810

    54. Akos005145756

    55. Akos016003409

    56. Tox21_112663_1

    57. Ccg-220621

    58. Cs-1997

    59. Db12523

    60. Ks-1139

    61. Ncgc00344565-01

    62. Ncgc00344565-04

    63. 4(1h)-pyrimidinone, 2-((1-(1-((4-fluorophenyl)methyl)-1h-benzimidazol-2-yl)-4-piperidinyl)methylamino)-

    64. Sl850324

    65. Smr003965484

    66. Sl-850324

    67. Ft-0628955

    68. M2756

    69. D01117

    70. T71584

    71. Ab01566892_01

    72. 612m459

    73. A801901

    74. Q417830

    75. J-507624

    76. Brd-k21884483-001-01-1

    77. (4-ethoxy-2-oxo-2,5-dihydro-pyrrol-1-yl)-aceticacid

    78. 2-({1-[1-(4-fluoro-benzyl)-1h-benzoimidazol-2-yl]-piperidin-4-yl}-methyl-amino)-3h-pyrimidin-4-one

    79. 2-({1-[1-(4-fluorobenzyl)-1h-benzimidazol-2-yl]-piperidin-4-yl}-methylamino)-4(1h) Pyrimidinone

    80. 2-[[1-[1-[(4-fluorophenyl)methyl]-2-benzimidazolyl]-4-piperidinyl]-methylamino]-1h-pyrimidin-6-one

    81. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]- Methylamino]-1h-pyrimidin-6-one

    82. 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methyl-amino]-1h-pyrimidin-6-one

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 432.5 g/mol
    Molecular Formula C24H25FN6O
    XLogP33.2
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count5
    Exact Mass432.20738760 g/mol
    Monoisotopic Mass432.20738760 g/mol
    Topological Polar Surface Area65.8 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity728
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Histamine H1 Antagonists, Non-Sedating

    A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)

    4.2 ATC Code

    R06AX25

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    R - Respiratory system

    R06 - Antihistamines for systemic use

    R06A - Antihistamines for systemic use

    R06AX - Other antihistamines for systemic use

    R06AX25 - Mizolastine